Approximately 16 boys with Duchenne Muscular Dystrophy (DMD), including several teenagers, are set to benefit from the drug, ...

As with recent rejections for Biogen and Scholar Rock, manufacturing issues stymied a regulatory bid from Fortress Biotech ...

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by ...

Emily Blunt Calls AI Actress Tilly Norwood ‘Really Scary' and Warns Hollywood Agencies: ‘Don't Do That' The 'stupidity' of ...

Satellos Bioscience is planning a Phase 2 trial in the U.S. to test SAT-3247 in children with Duchenne who are able to walk.

Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.

Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy. Click here to find out why CAPR stock is a ...

Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

– Late-breaking presentation at ESC Congress 2025 confirms that early, persistent lowering of LDL-C and blood pressure leads to improved cardiovascular health outcomes – – Raised over $50 million to ...